•Advertising Disclosures •Auctions •Car Ads •Car Loans •Children's Ads •Comparative Ads •Consumer Lease •Cotton •Dairy •Deceptive Pricing •Diamonds •Diet Programs •Diet Supplements •Down •E-Mail Ads •Endorsements •Environment/Guide •Environment/Mail •Eye Care •Eye Surgery •Food Ads •Fur •Gems •Health Claims •Hearing Aids •Home Financing •Indoor Tanning •Internet Ads •Internet Mktng. •Infertility Svcs. •Jewelry •Made in USA #1 •Made in USA #2 •Made in USA #3 •Made in USA #4 •Milk •MLM #1 •MLM #2 •Pearls •Precious Metals •Recycling •Retail Electricity •Spam •Testimonials •Timeshare Tips •Unfairness •Use of Word "Free" •Vacation Plans •Varicose Veins •Wool •Yellow Pages Our Related Websites Advertising Compliance Service Advertising Substantiation Ad Substantiation Green Advertising Law Political Advertising Law

ALLEGEDLY BOGUS "GOLD CARD" MARKETERS SETTLE FTC CHARGES Operators of a plan sold "gold cards," representing them as Visa or MasterCards. However, these operators provided their own "merchant cards" that limited consumer use to purchases from their own catalogs or websites. These operators settled FTC charges that the "scheme" was deceptive and violated federal law. The Court orders stemming from the settlements bar the operators from marketing any credit or merchant cards and from falsely claiming they will help consumers improve their credit by reporting credit histories to the credit reporting agencies. The orders also bar defendants from misrepresenting any product or service they're selling and requires that they disclose all information material to a consumer's decision to buy a product or service before sale. The defendants also are barred from deceptively charging for expedited delivery. NOTE: Stipulated final judgments and orders are for settlement purposes only and do not constitute an admission by the defendant of a law violation. Because these orders were signed by the judge in the case, they have the force of law. (Salyon, Inc., et al., FTC File No. 01 23124, November 7, 2002.) Watch the latest videos on YouTube.com FDA, PHARMACIA UPDATE BEXTRA LABEL WITH NEW WARNINGS The Food and Drug Administration (FDA) and Pharmacia are advising health care professionals about new warnings and information in the product labeling of the drug Bextra (valdecoxib). Bextra is a drug approved for treatment of osteoarthritis, rheumatoid arthritis and dysmenorrhea (menstrual pain). The labeling is being updated with new warnings following postmarketing reports of serious adverse effects including life-threatening risks related to skin reactions -- including Stevens Johnson Syndrome, and anaphylactoid reactions (serious allergic reactions). Also, the labeling will state that the drug is contraindicated -- not to be used -- in patients allergic to sulfa containing products. (Dear Healthcare Professional Letter, T02-43, November 15, 2002.)

Main Archived News Index: 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 Archived 2001 News: January | February | March | April | May | June | July | August | September | October | November | December     Advertising Compliance Service...

	Enter your search terms Submit search form
	Web www.lawpublish.com

© Copyright 2002-2008 JLCom Publishing Co., L.L.C. All rights reserved.

IMPORTANT NOTICE: The materials that are included in this Web Site are intended for general information purposes only and are not intended to provide, and do not constitute, legal or other advice. Persons who need legal or other services should contact a duly licensed professional. The inclusion of links on this Web Site are to Web Sites maintained by third parties over whom JLCom Publishing Co., LLC has no control. Such links do not imply endorsement of the material contained therein. JLCom Publishing Co., LLC makes no claims, representations, or warranties as to the accuracy, completeness, or appropriateness of these Web Sites or the information these websites contain. Read this disclaimer and our privacy statement before using this site.